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Nasopharyngeal carcinoma (NPC) is the most
common cancer originating in the nasopharynx, and
is extremely common in southern regions of China.
Although the standard combination of radiotherapy
and chemotherapy has improved the efficiency in
patients with NPC, relapse and early metastasis are
still the common causes of mortality. Cancer stem-like
cells (CSCs) or tumor initial cells are hypothesized to
be involved in cancer metastasis and recurrence. Over
the past decade, increasing numbers of studies have
been carried out to identify CSCs from human NPC
cells and tissues. The present paper will summarize
the investigations on nasopharyngeal CSCs, including
isolation, characteristics, and therapeutic approaches.
Although there are still numerous challenges to translate
basic research into clinical applications, understanding
the molecular details of CSCs is essential for developing
effective strategies to prevent the recurrence and
metastasis of NPC.According to the CSC model, cancers are hierarchicallyIntroduction
Nasopharyngeal carcinoma (NPC) is a distinct malignancy
of the nasopharynx, the uppermost region of the pharynx.
NPC is highly prevalent in southern China and southeast-
ern Asia (incidence is between 25 and 50/100,000), but is
rare in the United States and most other nations (incidence
< 1/100,000) [1]. More than 90% of NPC patients are ini-
tially diagnosed as type II or type III undifferentiated and
nonkeratinizing carcinoma [2]. Epstein–Barr virus (EBV)* Correspondence: shuping@csu.edu.cn; ligy@xysm.net
†Equal contributors
1Hunan Provincial Tumor Hospital and the Affiliated Tumor Hospital of
Xiangya School of Medicine, Central South University, 582 Xianjiahu Road,
Changsha, Hunan 410013, China
2Cancer Research Institute of Xiangya Medical School, Central South
University, 110 Xiangya Road, Changsha, Hunan 410078, China
Full list of author information is available at the end of the article
© Wei et al.; licensee BioMed Central Ltd
months following its publication. After this tim
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
2014infection, environment and diet, and genetic factors all
contribute to the development of NPC [3].
Radiotherapy or combined chemoradiotherapy shows a
cure rate >90% in patients with early-stage NPC [4], but
significant rates of distant relapse and metastasis still occur
in patients after radiotherapy or chemoradiotherapy. Al-
though much progress has been gained in recent years, the
5-year survival rate is only 50 to 60% [5]. The leading cause
of mortality is attributed to local recurrence and metasta-
sis. Although numerous molecular targeting agents have
been developed due to deeper understanding of the disease
progression, local recurrence still occurs in 15 to 58% [6],
and the rate of nasopharynx and cervical lymph node re-
currence is between 12.0 and 22.0% of patients who under-
went standard chemotherapy and radiotherapy treatment
during 5 years [7]. Thus it is crucial to develop effective
strategies to attack cancer cells that become resistant to
current chemotherapy.
In recent years, one of the major mechanisms for
post-therapeutic recurrence of NPC has been suggested
by the cancer stem-like cell (CSC) proposition [8-10].
organized similar to normal tissues and cancer growth
and progression are driven by a small subpopulation of
tumor cells with stem cell-like properties, the CSCs.
This rare cell subpopulation is responsible for tumor ini-
tiation, maintenance and regeneration. CSCs have been
identified in various human malignancies such as brain
cancer [11], breast cancer [12], colon cancer [13,14],
pancreatic cancer [15,16], and so forth.
In this paper we will summarize the studies on NPC
CSCs, including isolation, characteristics, and thera-
peutic approaches.Experimental evidence for nasopharyngeal
carcinoma cancer stem-like cells
Recent investigations into NPC CSCs are summarized in
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Table 1 Reports of expression/functional profiles recently found to identify putative human nasopharyngeal cancer
stem-like cells
Expression/functional profile Cells/tissues studied Characteristics of cancer stem cell identity
Label-retaining cells 5-8 F, 6-10B and TMNE Increased clonogenicity, tumor formation in mice at low titers [16,17]
Label-retaining cells (PKH26+) CNE1, CNE2, SUNE1, and HONE1 Longevity, sphere formation, side population cells, and resistance to
radiotherapy [18]
Side population cells CNE-2 Strong tumorigenesis ability, more resistant to chemotherapy and
radiotherapy, cytokine 19 positive [24]
Side population cells (ABCG2+) 5-8 F ABCG2 alone is not sufficient, PSCA, ABCG2 and ALP were expressed in
ABCG2+ cells, and K19, integrin α6, integrin β4, CD44 and K14 were
expressed in ABCG2− cells [25]
ALDH1high cells or ALDH1A1 5-8 F and CNE2 High ALDH1 activity, higher clone formation efficiency, differentiation
capability and higher migration, enhanced capacities of growth,
proliferation, and tumorigenesis,5 to 103 ALDH1high NPC cells required to
induce tumors, vimentin+, and E-cadherin−,OCT4, SOX2 and Nanog+
[27,28]
C666-1 Significantly greater ability to proliferate, be clonogenic, resist
chemotherapy drugs and radiation, and express pluripotent markers,
tumor formation at a higher rate [29-31]
CD44+ 5-8 F, C666-1 Higher survival rate, resist chemotherapy drugs [35,36]
CD133+ CNE2 and primarily cultured NPC cells Nanog+ and Sox2+, a strong potential for self-renewal, sphere formation,
proliferation and differentiation and a greater potential for in vivo tumor
formation in nude mice [39]
Sphere-forming cells C666-1 CD44+ and SOX2+, higher spheroid formation efficiency, resistant to
chemotherapeutic agents, CCR7+ associated recurrent disease and
distant metastasis [48]
ABCG2 ATP-binding cassette sub-family G member 2; ALDH1 aldehyde dehydrogenase 1; NPC nasopharyngeal carcinoma.
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Adult stem cells can be identified by the label-retaining cell
(LRC) approach based on their ability to retain nucleoside
analogs, such as bromodeoxyuridine. Zhang and colleagues
identified LRCs from nasopharyngeal epithelia when neo-
natal mice were intraperitoneally injected with bromodeox-
yuridine [17]. Long-term bromodeoxyuridine-labeled LRCs
(2% of cells) were detected in the adult mice nasopharyn-
geal epithelia by immunostaining, and some LRCs (12% of
cells) were found to be recruited into the S phase of the
cell cycle with an additional radioactive thymidine-labeling
technique, indicating that the stem cells also divide, most
probably asymmetrically. In addition, three NPC cell lines
(5-8 F, 6-10B and TMNE) were labeled with bromodeox-
yuridine in vitro and then individually engrafted into the
back of nude mice, where the tumors develop. Label-
retaining stem cells were found in all three kinds of NPC
xenograft tumors (0.3% of cells), around 16% of which
were also labeled with radioactive thymidine. The presence
of epithelial LRCs in mouse nasopharynx and human NPC
tissues was demonstrated, and these stem-like LRCs are
not completely quiescent as they can be recruited into the
cell cycle to participate in the physiological or pathological
process at any moment. Jiang and Yao also verified LRCs
existing in NPC cell line 5-8 F [18]. Bromodeoxyuridine
was detected in 5-8 F cells and xenograft tumors. After
8 weeks, only sporadic LRCs were detected in xenograft tu-
mors, and these LRCs were located at the cancer margin.The existence of LRCs in 5-8 F cells indicates the existence
of cancer stem cells in NPC.
PKH26 is a lipophilic marker that intercalates into the
membranes of viable cells and is not transferred between
cells. A stem cell-like subpopulation (PKH26+) was identi-
fied in NPC cell lines using a label-retention technique
[19]. PKH26+ cells were enriched for clonogenicity, sphere
formation, side population (SP) cells, and resistance to
radiotherapy. They also found that proto-oncogene c-MYC
regulates radiotolerance through transcriptional activation
of CHK1 and CHK2 checkpoint kinases by binding to the
promoters using genomic approaches. Overexpression of
c-MYC in the PKH26+ subpopulation leads to increased
expression of CHK1 and CHK2 and subsequent activation
of the DNA damage-checkpoint response, resulting in
radioresistance. Furthermore, loss of CHK1 and CHK2 ex-
pression reverses radioresistance in PKH26+ cells in vitro
and in vivo. This study elucidates the role of the c-MYC-
CHK1/CHK2 axis in regulating DNA damage-checkpoint
responses and stem cell characteristics in the PKH26+ sub-
population. Furthermore, these data reveal a potential
therapeutic application in NPC.
Side population cells
SP cells in tumors are a small subpopulation of cancer
cells with stem-like properties that can be identified by
flow cytometry analysis based on their high ability to ex-
port certain compounds such as Hoechst 33342 and
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mors is considered a key factor contributing to drug re-
sistance and metastasis [20-24], and presents a major
challenge in cancer treatment. SP cells have been iso-
lated from several solid tumors. NPC is characterized by
lymph node of the neck and cranial nerve involvement
at the early stage when the primary tumor is small or
not obvious. Wang and colleagues isolated SP cells from
five NPC cell lines and investigated stem cell character-
istics, such as proliferation, self-renewal, and differenti-
ation [25]. They observed a strong tumorigenic ability of
SP cells following in vivo transplantation into immuno-
deficient mice. SP cells were found to be more resistant
to chemotherapy and radiotherapy, and this was related
to the ATP-binding cassette half-transporter member 2
of G family protein and smoothened protein expression,
respectively. These data showed that SP cells in human
NPC cell line CNE-2 had stem cell characteristics
in vitro but also showed that they had a strong ability to
form tumors in vivo.
ATP-binding cassette sub-family G member 2
(ABCG2) transports various molecules across extracellu-
lar and intracellular membranes. High ABCG2 expres-
sion subpopulation cancer cells are associated with
multidrug resistance. The SP phenotype is mainly medi-
ated by ABCG2. Zhang and colleagues isolated ABCG2+
cells in 5-8 F NPC cells and compared their tumorigenic
potential with ABCG2− cells using the magnetic cell
sorting method [26]. Cell cycle analysis indicated that
ABCG2+ cells were mostly quiescent, and they showed
lower cloning efficiency and tumorigenicity than ABCG2−
cells. Using the Affymetrix human whole genome ex-
pression chip to identify the gene expression profile of
ABCG2+ and ABCG2− cells, both subpopulations
expressed some stem cell-associated genes; for example,
PSCA, ABCG2 and ALP were expressed in ABCG2+
cells, and K19, integrin α6, integrin β4, CD44 and K14
were expressed in ABCG2− cells, suggesting there were
stem cells in both ABCG2+ and ABCG2− cells. This ob-
servation demonstrated that there exist ABCG2+ cells in
NPC cells, but ABCG2 alone is not sufficient for isolat-
ing cancer stem cells in 5-8 F NPC cells. Similar results
have been obtained in other tumors [27]. This evidence
indicates that ABCG2 alone should not be a reliable
stem cell marker.
ALDH1high cells
Aldehyde dehydrogenase 1 (ALDH1) belongs to the al-
dehyde dehydrogenase superfamily, which is responsible
for the oxidation of aldehydes to their corresponding
carboxylic acids. ALDH1 was first used as a marker of
cancer stem cells in hematopoietic cells [28]. Wu and
colleagues isolated ALDH1+ cells from human NPC cell
lines (5-8 F and CNE2) and found that ALDH1+ cancercells grew faster and had higher clone formation effi-
ciency, differentiation capability and higher migration
than ALDH1− cancer cells in vitro [29]. In addition,
ALDH1+ cancer cells formed significantly more tumor
spheres. In vivo experiments showed that only 5 to 103
ALDH1+ NPC cells were required to induce tumors.
Notably, ALDH1+ cells were enriched in the SP and
stem cell-like genes OCT4, BMI1, KLF4 and SOX2 are
preferentially expressed in ALDH1+ cells. The expres-
sion of ALDH1 correlated significantly with TNM classi-
fication and epithelial–mesenchymal transition (EMT)
markers including vimentin expression and loss of
E-cadherin.
ALDH1 might be a novel stem cell marker and a valu-
able predictor of NPC with poor survival [30]. Yu and
colleagues showed that enriched CSCs with high ALDH
activity in C666-1 were associated with a significantly
greater ability to proliferate, be clonogenic, resist chemo-
therapy drugs and radiation, reconstitute a heteroge-
neous population, and express pluripotent markers [31].
Two groups have investigated the expression of
ALDH1A1 in NPC specimens [32,33]. Their findings in-
dicated that increased expression of ALDH1A1 in NPC
was associated with stem-like properties.
CD44+ cells
CD44 is a cell-surface glycoprotein involved in cell–cell
interactions, cell adhesion and migration. CD44 cells are
reported as cell surface markers for some breast and
prostate cancer stem cells [34,35]. Su and colleagues iso-
lated CD44+ cells from NPC cell line 5-8 F by
fluorescence-activated cell sorting [36]. CD44 was posi-
tively expressed in 52.5% of the 5-8 F cell line. Regard-
less of the culture conditions, with or without serum,
freshly sorted CD44 cells showed stronger proliferative
capacity than CD44− and unsorted cells. The expression
levels of B-lymphoma Mo-MLV insertion region 1
homolog (Bmi-1) and Oct-4 mRNA in CD44+ cells were
significantly higher than for CD44− cells. This study in-
dicated that CD44+ cells have the biological characteris-
tics of CSCs or cancer progenitor cells (CPCs):
pluripotent marker expression, high self-renewal ability,
and chemoresistance and radioresistance. Janisiewicz
and colleagues reported that CD44+ cells differentiated
into CD44− cells in C666 cells [37]. CD44+ cells exhib-
ited tumor-initiating capacity in the xenograft model.
Patient tumors were heterogeneous for CD44 staining,
and CD44 expression is associated with clinical out-
come. These observations indicated that the CD44+ sub-
population has features consistent with CSCs.
The expression of CD44 and its role as a marker of
cancer stem cells in the head and neck is interesting. Re-
cent publications have pointed out the role of CD44 as a
CSC marker in the early diagnosis of head and neck
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lapse, recurrence of disease and chemo/radioresistance
[38,39]. As this point, CD44 is correlated with the out-
come and prognosis in head and neck squamous cell
cancer and is associated with cancer stem cells if com-
bined with other surface markers of cancer stem cells.
CD133+ cells
CD133 is a member of pentaspan transmembrane glyco-
proteins (5-transmembrane), which specifically localize
to cellular protrusions. CD133 has been found to be
expressed in hematopoietic stem cells, endothelial pro-
genitor cells, glioblastoma, neuronal and glial stem cells
and various pediatric brain tumors. A CD133+ cell popu-
lation was enriched using magnetic-activated cell sorting
technology in NPC cell line CNE2 by Wen’s group [40].
CD133+ cells exhibited a stronger potential for self-
renewal, proliferation and differentiation and a greater
potential for in vivo tumor formation in nude mice com-
pared with CD133− cells, although the percentage of
CD133+ cells was small. These results suggest that
CD133 may serve as a specific surface marker for naso-
pharyngeal cancer stem cells.
Other factors
Bmi-1 has been reported as an oncogene by regulating
p16 and p19, which are cell cycle inhibitor genes. Bmi-1
is necessary for efficient self-renewing cell divisions of
adult hematopoietic stem cells as well as adult peripheral
and central nervous system neural stem cells. Overex-
pression of Bmi-1 has been found in various malignant
tumors as well as in NPC [41]. Upregulation of Bmi-1
induced EMT and enhanced the motility and invasive-
ness of human nasopharyngeal epithelial cells, while
Bmi-1 depletion enhanced the chemosensitivity of NPC
cells by inducing apoptosis. Bmi-1 was therefore as-
sumed to be a candidate cancer stem cell marker [36].
In the literature there are reports that corroborate the
role of Bmi-1 as a prognostic factor for local recurrence
and distant metastases in laryngeal carcinoma [42,43].
Sphere-forming cells
The sphere culture assay has been used to enrich the po-
tential CSC subpopulations when the specific CSC
makers have not been defined, as is the case for most
CSCs [44-48]. The character relies on their property of
anchorage-independent growth in serum-free medium.
Lun and colleagues reported that sphere-forming cells
were isolated from an EBV-positive NPC cell line C666-
1 and its tumor-initiating properties were confirmed
[49]. Both CD44 and SOX2 were found to be overex-
pressed in a majority of sphere-forming C666-1 cells.
The CD44+SOX2+ cells were detected in a minor popu-
lation in EBV-positive xenografts and primary tumorsand were considered as potential CSCs in NPC. Notably,
the isolated CD44+SOX2+ NPC cells were resistant to
chemotherapeutic agents and had higher spheroid for-
mation efficiency, showing CSC properties.
Model on origin of nasopharyngeal carcinoma
cancer stem-like cells
The origin of CSCs is still controversial. Several hypoth-
eses indicate that their origin may be heterogenic
(Figure 1).
Loss of differentiation of nasopharyngeal mucosa B
lymphocytes or epithelial cells
NPC is predominantly undifferentiated and nonkerati-
nizing. The vast majority of cases of this cancer reveal
not only varying degrees of squamous differentiation,
but also more or less preserved traces of the columnar
cell differentiation under electron microscopy. In other
words, NPC is a kind of biphasic malignant tumor with
squamous differentiation with a slight advantage [50].
EBV genome analysis in the tumor cells shows that only
one fusion terminal fragment exists, suggesting that viral
DNA of all NPC cells is homologous and originates from
the same clone proliferation [51]. Viral DNA present in
the EBV-infected lymphocytes infiltrated inside the
tumor can be easily traced by polymerase chain reaction
amplification [52,53]. One may therefore suggest a hy-
pothesis: B lymphocytes are not terminally differentiated
cells or the B-cell terminal differentiation capacity can
be reversed by the role of a certain factor, and then by
the nasopharyngeal mucosa. B lymphocytes may be the
progenitor cells of NPC. However, there is still no evi-
dence to support this hypothesis.
EBV-encoded small RNA signals were also recently de-
tected in the nuclei of NPC cells, and occasionally in a
limited number of infiltrating lymphocytes by quantum-
dot fluorescent in situ hybridization [54]. In fact, the
nasopharyngeal epithelial cells with some prior genetic
changes are prone to transformation, and then premalig-
nant lesions and the concurrent detection of dysplasia
and invasive carcinoma of epithelial cells occur. The
viral episome is maintained in the infected epithelial cell,
which continues to proliferate and does not differentiate
[50]. This means that the transformation of nasopharyn-
geal epithelial cells with genetic modifications attacked
by EBV may also be the origin of NPC CSCs.
Epithelial–mesenchymal transition induces cancer stem/
progenitor-like cells
Evidence has been found that the principal oncoprotein of
EBV, latent membrane protein 1 (LMP1) [55] – which is
associated with human malignancies, especially NPC –
promotes tumor cell invasion and metastasis, as well as
the EMT. Horikawa and colleagues [55] reported that
Figure 1 Model for origin of nasopharyngeal carcinoma stem or stem-like cells. BL, B lymphocytes; CSC, cancer stem-like cell; EBV, Epstein–
Barr virus; EMT, epithelial–mesenchymal transition; MET, mesenchymal–epithelial transition; NE, nasopharyngeal epithelial cells; NPC, nasopharyngeal
carcinoma; NSC, normal stem cell; TIC, tumor-initiating cell.
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phenotype as well as self-renewal abilities in LMP1-
expressing epithelial NPC cell lines. LMP1 increased the
expression of several CPC markers as well as producing
increased levels of EMT markers. These findings indicate
that LMP1 can induce CPC-like properties in epithelial
cells and suggest that LMP1-induced phenotypic changes
contribute to the development of NPC. At the apex of the
hierarchy are primitive rare CSCs, which possess extended
self-renewal capabilities that allow the cells to perpetuate
themselves and develop into CPCs. These CPCs have only
limited self-renewal abilities and can, in turn, differentiate
into various types of cancer cells. In vivo, the primitive
rare CSCs rarely divide, whereas CPCs proliferate rapidly.
In addition, latent membrane protein 2a also has similar
roles in inducing EMT [56,57].
Induction of EMT in tumor cells not only promotes
tumor cell invasion and metastasis, but also contributes
to drug resistance [25,58-61]. These processes are con-
sistent with the acquisition of a CSC phenotype that is
also known as stemness characteristics [62]. Although
CSCs may form in such a way, EMT acts as part of the
process and mesenchymal cells partly have the proper-
ties of cancer stem cells.
Originating from normal stem cells
CSCs share similar properties with normal stem cells,
such as a long lifespan, induction of angiogenesis,resistance to apoptosis, ability for self-renewal and dif-
ferentiation, expression of stem cell markers, and so
forth [46]. Normal nasopharyngeal stem reserve cells of
columnar epithelium and the basal cells of squamous
epithelium stem cells, especially basal cell foci of squa-
mous metaplasia, have been considered the origin of
NPC cells. Zhang and coworkers first described the
identification of stem-like cells in normal mouse naso-
pharyngeal epithelium with the well-established LRC ap-
proach [17]. EBV infection, environment and diet, and
genetic factors can promote the transformation and ab-
normal differentiation of normal stem cells, which may
be a derivative of NPC CSCs.
Therapeutic approaches targeting
nasopharyngeal cancer stem-like cells
Ongoing studies show that targeting CSCs may be a
quite promising strategy. Based on the properties of
NPC CSCs, many attempts have been developed to tar-
get NPC CSCs specifically (Figure 2).
Nigericin was recently reported to target CSCs select-
ively and to sensitize CSCs in NPC to the widely used
clinical drug cisplatin both in vitro and in vivo. Nigericin
decreased the SP percentages in S18 cells (higher meta-
static ability) and S26 cells (much lower metastatic abil-
ity) derived from the NPC cell line CNE-2. The
downregulation of the polycomb group protein Bmi-1
was found to contribute to the inhibitory effect of
Figure 2 Potential therapeutic approaches targeting nasopharyngeal carcinoma stem cells or stem-like cells. Ab, antibody; CCR7,
CC-chemokine receptor 7; CPC, cancer progenitor cell; DAPT, (N-((3,5-difluorophenyl)acetyl)-L-alanyl-2-phenyl)glycine-1,1-dimethylethyl ester; EGCG,
epigallocathechin gallate; GSI, inhibitor of γ-secretase; NPC, nasopharyngeal carcinoma; SP, side population; TK, tyrosine kinase.
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CCR7 antibody abolished the sphere-forming ability of
C666-1 in vitro [49].
Shen and colleagues found that resveratrol impeded
CSC properties through the activation of p53 and this
effect could be reversed by knockdown of p53. Further-
more, resveratrol suppressed the stemness and EMT
through reactivating p53 and inducing miR-145 and
miR-200c, which were downregulated in NPC CSCs
[63]. Epigallocathechin gallate, the most abundant cat-
echin in green tea, has been reported to regulate NPC
CSCs and their self-renewal capacity, and inhibited their
invasive characteristics [64]. Smac mimetics in combin-
ation with TRAIL selectively target cancer stem cells, re-
duce the percentage of SP cells, inhibit colony-forming
and sphere-forming abilities, and eliminate NPC stem
cells in xenograft mice [65].
Notch signaling is important for the self-renewal and
maintenance of stem cells. In cancer stem cells, the sig-
naling pathway commonly is activated. Yu and col-
leagues reported that the Notch inhibitor, (N-((3,5-
difluorophenyl)acetyl)-L-alanyl-2-phenyl)glycine-1,1-
dimethylethyl ester, could reduce the proportion of SP
cells from the NPC cell line CNE1,2 [66] . This ester
inhibited NPC cell proliferation, depleted SP cells, re-
duced colony formation, and tumor formation of xeno-
graft in immune-deficient nude mice, and induced
apoptosis of NPC cells. This study shows that Notch
pathway inhibition may be a promising clinical approach
in CSC-targeting therapy for NPC.
The epidermal growth factor receptor pathway plays a
critical role in regulating CSCs [67]. The effects of epi-
dermal growth factor receptor on maintaining CSCs aremainly mediated by AKT signaling, and β-catenin is re-
sponsible for governing CSC properties in response to
epidermal growth factor receptor/AKT activation.
Tumor cells derived from cisplatin-treated mice grew
rapidly, whereas regrowth of tumor cells from gefitinib-
treated mice was severely diminished. Expression of epi-
dermal growth factor receptor correlates with expression
of β-catenin and nanog in primary tumor specimens
from NPC patients. These findings provide mechanistic
and preclinical evidence supporting the use of gefitinib
alone or in combination with a chemotherapeutic agent
in the therapy for patients with NPC. Targeting
β-catenin is suggested to represent a rational clinical
strategy for CSCs harboring activated epidermal growth
factor receptor or AKT.
The hedgehog pathway, a pathway implicated in the
maintenance of stem cells, is activated by the binding of
a hedgehog ligand (Sonic hedgehog) to the transmem-
brane protein receptor Patched, releasing the inhibition
of Smoothened and then activating downstream signal-
ing components and Gli-mediated transcription of target
genes. EBV activates the hedgehog signaling pathway
through autocrine induction of Sonic hedgehog ligand
[68,69]. Blocking the pathway with cyclopamine, a spe-
cific inhibitor of the Sonic hedgehog signaling pathway,
reduced the proliferation of NPC epithelia cell lines and
induced the apoptosis of NPC cells.
Conclusion and future perspectives
From the biological behavior of the EBV and nasopha-
ryngeal cancer-specific cell surface markers, we hypothe-
sized that the generation of NPC may be derived from
undifferentiated clonal expansion of B lymphocytes or
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programming or mutation of normal nasopharyngeal
epithelial cells. These assumptions still require further
experimental evidence. Similar to the heterogeneous na-
ture of solid cancers, the origin of cancer stem cells in
different individuals with the same type may vary due to
epigenetic, genetic and tumor microenvironment factors.
Although many of the studies showed that these com-
pounds have considerable promise, few provided com-
prehensive evidence showing that the proposed agents
were specific to NPC CSCs and were considerably more
effective than conventional therapy (radiation, cisplatin,
and so forth). These proposed treatments still require
further investigation, especially through rigorous in vivo
experimentation, before they can be considered true po-
tential CSC inhibitors and considered for use in clinical
trials.
The investigations into the specific NPC CSCs and
clinical therapeutic trials have been ongoing. However,
there remains much to do in improving the therapeutic
target specific for NPC CSCs. Several factors should be
considered; first, the reliability of using cell surface
markers or functional screening as a method to isolate
CSCs remains controversial. Golebiewska and colleagues
have reported that SP cells in human glioblastoma are
non-neoplastic and are exclusively stroma derived [70].
ABCG2+ and ALDH1high cannot act alone as cancer
stem cells biomarkers [26,71,72]. A second factor is that
the heterogeneous nature of NPC cells and NPC CSCs
requires obtaining an individualized treatment plan.
More investigations are therefore required to acquire the
primary characteristics and the molecular regulation ex-
pression profile in cancer stem cells.
CSCs from various tissues appear to be more resistant
to chemotherapeutic reagents than do mature cell types
and characteristically express drug-resistance proteins. If
this was true of NPC CSCs, therapies targeting CSCs
directly should result in more reliable responses for pri-
mary as well as metastatic disease. The sensitivity of
CSCs to the different strategies requires more experi-
mental evidence confirmed both in vitro and in vivo.
With these targets known, this fraction of cancer cells
that can rapidly develop the critical tumor cell mass can
be eliminated (Figure 2). Consequently, defining the
unique properties of NPC CSCs remains a high priority
for developing early diagnostic and effective therapeutic
strategies against NPC.Abbreviations
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